In Depth 15 Aug 2022Can phage therapy answer the booming antibiotic resistance problem? Antibiotic-resistant superbugs cause a large number of deaths around the world each year, but effective new antibiotics are thin on… August 15, 2022 - 8 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
In Depth 30 Dec 2020A Look Back at the Past Decade of European Biotech As we prepare to enter a new decade, we look back on the major milestones and blunders within European biotech… December 30, 2020 - 15 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
In Depth 21 Dec 2020Enemy or Valuable Ally? How Biotech Uses Viruses for Good Taking advantage of the ability of viruses to manipulate life is opening new doors for the biotech industry. Once only… December 21, 2020 - 7 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
News and Trends 29 Apr 2020Pluristem Scores €50M From EIB to Develop Covid-19 Cell Therapy Israeli cell therapy biotech Pluristem Therapeutics has secured up to €50M in non-dilutive funding from the European Investment Bank to… April 29, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2019Austrian Biotech Will Develop Viral Protein For Vaginal Infection The Austrian biotech company PhagoMed Biopharma is developing a viral protein that could one day treat the common condition bacterial… October 22, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2019Microbiome Biotech Will Use Series B to Bring Treatments to Clinic The Israeli biotech BiomX has raised €28M ($32M) to advance its treatments for acne and inflammatory bowel disease to the… February 21, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Nov 2018Genentech and Immunocore Expand Partnership to Develop Cancer Immunotherapy Immunocore and the US biotech giant Genentech are building on their existing partnership to boost the clinical development of Immunocore's… November 20, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 25 Jul 2018Could These Groundbreaking Therapies Make Conventional Antibiotics a Thing of the Past? With the rise of antimicrobial resistance across the globe, and with a dire lack of new antibiotics in the pipeline,… July 25, 2018 - 5 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
Interview 21 Mar 2018Do Phages Hold the Key to Modulating the Microbiome? The human microbiome is emerging as a target for treating a wide range of diseases, but it's still a young… March 21, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 21 Aug 2017German Biotech Starts Trials with a Personalized Cell Therapy for Multiple Cancers Immatics will start a first clinical trial to test IMA101, a personalized cell therapy with the potential to treat multiple… August 21, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2016The next generation of Antibiotics could be Bacteriophages One of the last remaining bastions for organic chemists in pharmaceuticals is in antibiotic development. It is now under fire… September 13, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2015The First Ever Oncolytic Immunotherapy is Set to Reach the European Market Amgen is now months away from a European approval with Imlygic (also known as T-VEC) - the first oncolytic immunotherapy for advanced… October 26, 2015 - 2 minutesmins - By Julie Lellouche Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2015Will bacteriophages solve the antibiotic resistance problem in the EU? French Pherecydes Pharma has launched the first EU clinical bacteriophage phase I/II trial to fight hospital acquired infections (HAIs) in… September 15, 2015 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jul 2015Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors Adaptimmune Therapeutics, an oxford-based company focusing on the use of T-cell therapies to treat cancer, announced today that data from its… July 22, 2015 - 3 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email